Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT04587830 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT04587830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04587830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Trial of ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme (GBM)
Lead sponsor
Polaris Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 14, 2020
Completion date
May 30, 2027
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (gbm)